Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab plus ipilimumab (N plus I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)

被引：0

作者：

Tannir, Nizar M.

McDermott, David F.

Escudier, Bernard

Hammers, Hans J.

Aren, Osvaldo Rudy

Plimack, Elizabeth R.

Barthelemy, Philippe

Neiman, Victoria

George, Saby

Porta, Camillo

Powles, Thomas

Donskov, Frede

Grimm, Marc-Oliver

Amin, Asim

Tykodi, Scott S.

Tomita, Yoshihiko

Rini, Brian I.

McHenry, M. Brent

Saggi, Shruti Shally

Motzer, Robert J.

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Dana Farber Harvard Canc Ctr, Beth Israel Deaconess Med Ctr, Boston, MA USA

[3] Gustave Roussy, Villejuif, France

[4] Univ Texas Southwestern, Dallas, TX USA

[5] Ctr Int Estudios Clin, Santiago, Chile

[6] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[7] Hop Univ Strasbourg, Strasbourg, France

[8] Rabin Med Ctr, Davidoff Canc Ctr, Petah Tiqwa, Israel

[9] Roswell Pk Canc Inst, Buffalo, NY USA

[10] Univ Pavia, Pavia, Italy

[11] Queen Mary Univ London, Royal Free NHS Trust, Barts Canc Inst, London, England

[12] Aarhus Univ Hosp, Dept Oncol, Aarhus, Denmark

[13] Jena Univ Hosp, Jena, Germany

[14] Atrium Hlth, Levine Canc Inst, Carolinas HealthCare Syst, Charlotte, NC USA

[15] Univ Washington, Seattle, WA 98195 USA

[16] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[17] Niigata Univ, Grad Sch Med & Dent Sci, Dept Mol Oncol, Dept Urol, Niigata, Japan

[18] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA

[19] Bristol Myers Squibb Co, Princeton, NJ USA

[20] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

609

引用

页数：3